

electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: January 19, 2001.

**Robert deV. Frierson,**

*Associate Secretary of the Board.*

[FR Doc. 01-2247 Filed 1-19-01; 5:04 pm]

BILLING CODE 6210-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality (AHRQ)

#### Statement of Organization, Functions, and Delegations of Authority

Part E, Chapter E (Agency for Healthcare Research and Quality), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (61 FR 15955-58, April 10, 1996, most recently amended 65 FR 16395, March 28, 2000) is further amended to reflect recent organizational changes. Specifically, AHRQ is re-titling its Center for Quality Measurement and Improvement as the Center for Quality Improvement and Patient Safety (CQIPS, pronounced "see quips") to reflect the Center's additional functional responsibilities for patient safety. The specific changes are as follows:

1. Under *Section E-10, Organization*, replace "I. Center for Quality Measurement and Improvement" with "I. Center for Quality Improvement and Patient Safety".

2. Under *Section E-20, Functions*, delete the title and statement for the Center for Quality Measurement and Improvement (EL) in its entirety and insert the following:

#### Center for Quality Improvement and Patient Safety (EL)

Conducts and supports research on the measurement and improvement of the quality of health care and enhancement of patient safety. Specifically, (1) Conducts and supports research, demonstrations, and evaluations of the quality of health care and patient safety; (2) conducts and supports research on the measurement of healthcare quality and promotes the use of these measures; (3) conducts and supports research on effective ways to improve the quality of healthcare and participates in the dissemination of this knowledge; (4) evaluates methods for identifying and preventing medical errors; (5) supports dissemination and communication activities to improve quality of care and patient safety; (6)

designs, conducts, and supports surveys to assess the quality of and satisfaction with health care services and systems; (7) develops and tests measures and methods for evaluating the quality of care and enhancing patient safety; (8) provides technical assistance and gathers information on the use of quality measures, consumer and patient information, and reporting on patient safety and the resulting effects; (9) develops and disseminates an annual report on healthcare quality in general and patient safety specifically; and (10) represents the Agency in meetings with domestic and international experts and organizations concerned with measuring and evaluating the quality of care and enhancing patient safety.

These changes are effective upon date of signature.

Dated: January 17, 2001.

**John M. Eisenberg,**

*Director.*

[FR Doc. 01-2064 Filed 1-23-01; 8:45 am]

BILLING CODE 4160-90-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Healthcare Infection Control Practices Advisory Committee: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92-463) of October 6, 1972, that the Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, has been renewed for a 2-year period extending through January 19, 2003.

For further information, contact Michele Pearson, M.D., Executive Secretary, Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, 1600 Clifton Road, NE, M/S E-69, Atlanta, Georgia 30333, telephone 404/639-6415 or fax 404/639-6459.

The Director, Management and Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 18, 2001.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 01-2107 Filed 1-23-01; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (P.L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Times and Dates:* 8:30 a.m.-6:45 p.m., February 21, 2001; 8 a.m.-3:15 p.m., February 22, 2001.

*Place:* Atlanta Marriott Century Center, 2000 Century Boulevard, N.E., Atlanta, Georgia 30345-3377.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

*Matters to be Discussed:* The agenda will include a discussion on the U.S. influenza surveillance summary; international update and vaccine selection for 2001-2002 influenza season; 2001-2002 control and prevention of influenza recommendations; update on live attenuated influenza vaccine; status report of ACIP statement on prevention of hepatitis B; update on thimerosal and DTaP vaccines; options to transition to thimerosal free DTaP vaccines; polio outbreak in the Dominican Republic; status of outbreak and control measures; policy implications for polio vaccine in the U.S.; stock pile of polio vaccine; update from the Haemophilus influenza b vaccine dose-reduction working group; smallpox vaccine recommendations; recommended use of vaccine for laboratorians working with highly-attenuated and non-attenuated strains of vaccinia virus or other or thopoxviruses; recommended use of vaccine in a bioterrorism event involving smallpox virus; recommendations regarding antiviral alternatives to VIG for treating vaccine adverse reactions; update from the National Center for Infectious Diseases; update from the National Immunization Program; update